Celcuity INC.
At a glance
EmployeesNot reported
In business since2017
HeadquartersMinneapolis, MN
SAM.gov UEIVYHXDAEA9CN5
Celcuity is a commercial-stage biotechnology company developing targeted therapies for solid tumors. The company's first approved product, REVTORPYK (gedatolisib), targets Class I isoforms of PI3K and mTOR complexes to block the PAM (PI3K/AKT/mTOR) pathway, and has FDA approval for treatment of HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer. The company is advancing a pipeline of additional targeted therapies focused on the PI3K/AKT/mTOR pathway.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Celcuity INC. | Minneapolis | MN | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.